Article Information
History
- July 17, 2021.
Article Versions
- Version 1 (June 15, 2021 - 13:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Iddo Z. Ben-Dov1,*,
- Yonatan Oster2,
- Keren Tzukert1,
- Talia Alster1,
- Raneem Bader3,
- Ruth Israeli1,
- Haya Asayag1,
- Michal Aharon1,
- Ido Burstein1,
- Hadas Pri-Chen1,
- Ashraf Imam3,
- Roy Abel1,
- Irit Mor-Yosef Levi1,
- Abed Khalaileh3,
- Esther Oiknine-Djian, PhD2,
- Aharon Bloch1,
- Dana G. Wolf2 and
- Michal Dranitzki Elhalel1
- 1Department of Nephrology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel
- 2Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel
- 3Department of Surgery, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel
- ↵*Correspondence: Dr. Iddo Ben-Dov, Department of nephrology, Hadassah Medical Center, Kiryat Hadassah 1, Jerusalem, Israel 921120, email iddo{at}hadassah.org.il, fax +97226446335
Posted July 17, 2021.
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months followup
